| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 5, 2004
Accepted on July 8, 2004
Department of Biochemistry and Nutrition and L. Deloyers Laboratory for Experimental Surgery, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium
* To whom correspondence should be addressed. E-mail: cdelport{at}ulb.ac.be.
The endogenous ligand for the growth hormone secretagogue receptor is ghrelin, a peptide recently purified from the stomach. Ghrelin is n-octanoylated on the Ser3 residue and this modification is essential for its interaction with the receptor. The degradation of ghrelin by rat and human serum, purified commercial enzymes and tissues homogenates was analyzed by combining HPLC and mass spectrometry. In serum, ghrelin was desoctanoylated, without proteolysis. The desoctanoylation was significantly reduced by phenylmethylsulfonyl fluoride (PMSF), a serine proteases and esterases inhibitor. In rat serum, the carboxylesterase inhibitor bis-p-nitrophenyl-phosphate (BNPP) totally inhibited ghrelin desoctanoylation and a correlation was found between ghrelin desoctanoylation and carboxylesterase activity. Moreover, purified carboxylesterase degraded ghrelin. Thus, carboxylesterase could be responsible for ghrelin desoctanoylation in that species. In human serum, ghrelin desoctanoylation was partially inhibited by eserine salicylate and sodium fluoride, two butyrylcholinesterase inhibitors, but not by BNPP and ethylenediamine tetraacetic acid (EDTA). Purified butyrylcholinesterase was able to degrade ghrelin, and there was a correlation between the butyrylcholinesterase and ghrelin desoctanoylation activities in human sera. This suggested that several esterases, including butyrylcholinesterase, contributed to ghrelin desoctanoylation in human serum. In contact with tissues homogenates, ghrelin was degraded by both desoctanoylation and N terminal proteolysis. We identified five cleavage sites in ghrelin between residues -Ser2-(acyl)Ser3- (stomach and liver), -(acyl?)Ser3-Phe4- (stomach, liver and kidney), -Phe4-Leu5- (stomach and kidney), -Leu5-Ser6- and -Pro7-Glu8- (kidney). In all cases, the resulting fragments were biologically inactive.
This article has been cited by other articles:
![]() |
E. Tham, J. Liu, S. Innis, D. Thompson, B. D. Gaylinn, R. Bogarin, A. Haim, M. O. Thorner, and J.-P. Chanoine Acylated ghrelin concentrations are markedly decreased during pregnancy in mothers with and without gestational diabetes: relationship with cholinesterase Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1093 - E1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Mayorov, N. Amara, J. Y. Chang, J. A. Moss, M. S. Hixon, D. I. Ruiz, M. M. Meijler, E. P. Zorrilla, and K. D. Janda Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice PNAS, November 11, 2008; 105(45): 17487 - 17492. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gjedde, E. T. Vestergaard, L. C. Gormsen, A. L. D. Riis, J. Rungby, N. Moller, J. Weeke, and J. O. L. Jorgensen Serum Ghrelin Levels Are Increased in Hypothyroid Patients and Become Normalized by L-Thyroxine Treatment J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2277 - 2280. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Liu, C. E. Prudom, R. Nass, S. S. Pezzoli, M. C. Oliveri, M. L. Johnson, P. Veldhuis, D. A. Gordon, A. D. Howard, D. R. Witcher, et al. Novel Ghrelin Assays Provide Evidence for Independent Regulation of Ghrelin Acylation and Secretion in Healthy Young Men J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1980 - 1987. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gauna, P. Uitterlinden, P. Kramer, R. M. Kiewiet, J. A. M. J. L. Janssen, P. J. D. Delhanty, M. O. van Aken, E. Ghigo, L. J. Hofland, A. P. N. Themmen, et al. Intravenous Glucose Administration in Fasting Rats Has Differential Effects on Acylated and Unacylated Ghrelin in the Portal and Systemic Circulation: A Comparison between Portal and Peripheral Concentrations in Anesthetized Rats Endocrinology, November 1, 2007; 148(11): 5278 - 5287. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. D. Delhanty, P. M. van Koetsveld, C. Gauna, B. van de Zande, G. Vitale, L. J. Hofland, and A. J. van der Lely Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an anti-apoptotic pathway Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E302 - E309. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. De Vriese, M. Hacquebard, F. Gregoire, Y. Carpentier, and C. Delporte Ghrelin Interacts with Human Plasma Lipoproteins Endocrinology, May 1, 2007; 148(5): 2355 - 2362. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rauh, M. Groschl, and W. Rascher Simultaneous Quantification of Ghrelin and Desacyl-Ghrelin by Liquid Chromatography-Tandem Mass Spectrometry in Plasma, Serum, and Cell Supernatants Clin. Chem., May 1, 2007; 53(5): 902 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Hauffa, K. Haase, I. M. Range, N. Unger, K. Mann, and S. Petersenn The Effect of Growth Hormone on the Response of Total and Acylated Ghrelin to a Standardized Oral Glucose Load and Insulin Resistance in Children with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 834 - 840. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. H. Park, Y. J. Oh, G. Y. Kim, S. E. Kim, K.-H. Paik, S. J. Han, A. H. Kim, S. H. Chu, E. K. Kwon, S. W. Kim, et al. Obestatin Is Not Elevated or Correlated with Insulin in Children with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 229 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nishi, H. Hiejima, H. Mifune, T. Sato, K. Kangawa, and M. Kojima Developmental Changes in the Pattern of Ghrelin's Acyl Modification and the Levels of Acyl-Modified Ghrelins in Murine Stomach Endocrinology, June 1, 2005; 146(6): 2709 - 2715. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. De Vriese, F. Gregoire, P. De Neef, P. Robberecht, and C. Delporte Ghrelin Is Produced by the Human Erythroleukemic HEL Cell Line and Involved in an Autocrine Pathway Leading to Cell Proliferation Endocrinology, March 1, 2005; 146(3): 1514 - 1522. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |